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Abstract
Background: Replicate experiments are often difficult to find in evolutionary biology, as this field is inherently an
historical science. However, viruses, bacteria and phages provide opportunities to study evolution in both natural
and experimental contexts, due to their accelerated rates of evolution and short generation times. Here we
investigate HIV-1 evolution by using a natural model represented by monozygotic twins infected synchronically at
birth with an HIV-1 population from a shared blood transfusion source. We explore the evolutionary processes and
population dynamics that shape viral diversity of HIV in these monozygotic twins.
Results: Despite the identical host genetic backdrop of monozygotic twins and the identical source and timing of
the HIV-1 inoculation, the resulting HIV populations differed in genetic diversity, growth rate, recombination rate,
and selection pressure between the two infected twins.
Conclusions: Our study shows that the outcome of evolution is strikingly different between these two “replicates”
of viral evolution. Given the identical starting points at infection, our results support the impact of random
epigenetic selection in early infection dynamics. Our data also emphasize the need for a better understanding of
the impact of host-virus interactions in viral evolution.
Background
Over the past few decades, evolutionary biology has had
an increasing impact on biomedical research [1-3]. Evo-
lutionary theory can address pertinent questions related
to the control of infectious diseases and particularly to
pathogen virulence [4]. RNA viruses serve as exciting
models for testing this theory because of their potential
for rapid evolution. For instance, a striking feature of
the Human Immunodeficienc yV i r u s1( H I V - 1 )i st h e
rapid population dynamics resulting in a high degree of
genetic diversity within and between infected individuals
[5,6]. The virus can then capitalize on this genetic diver-
sity to evade a host immune response [7,8]. Neverthe-
less, host-virus coevolution is also important with
respect to disease progression [9,10]. Viral evolution can
be strongly shaped through antiviral pressure applied by
the host’s immune system [11,12].
A few complications in the study of host-virus coevo-
lution are the different genetic backgrounds of the host
and the genetic diversity of the infecting viral popula-
tion. The model of monozygotic twins infected synchro-
nically through exposure to the same viral population,
therefore, provides an opportunity to examine the popu-
lation dynamics of HIV while holding a number of con-
founding variables constant. Here we exploit HIV-1 as a
model system [13] to examine the population genetic
processes and epigenetic influence on viral evolution.
We collected nucleotide sequence data from the genes
Protease (pro), Reverse Transcriptase (rt), and Envelope
(env) in each monozygotic twin. Using these data, we
estimated relevant population genetic parameters,
including recombination rates, genetic diversity, growth
rates, and selection pressure to compare between the
two host individuals. While these twins have identical
genetic backgrounds and were infected with the same
source of HIV (a common transfusion source collected
from one donor and administered simultaneously to
both twins at birth), they have remarkable differences in
their clinical courses. Twin A is almost normal in terms
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860 cells/μl for twin A; and 319 cells/μl for twin B) and
growth, whereas twin B is almost 5 years delayed in
terms of size and had many complications including a
rare neoplasm.
Recent studies focusing on monozygotic twins are
conflicting on whether HIV evolution can be predictable
[14,15] or unpredictable [16,17], related to the immuno-
logical repertoire recruitment in these hosts. Those stu-
dies examined immune responses, viral evolution, and
disease outcome in monozygotic twins infected simulta-
neously with the same virus. They showed that immune
selection driven by dominant sequences in each host
could contribute to specific pathways of HIV-1 evolu-
tion. The same natural model is also investigated here;
however we focus on the evolutionary processes acting
on HIV-1 evolution in identical twins by characterizing
the population genetic parameters, including positive
selection in the viral population. If the viral evolution is
predictable, we expect to see similar population
dynamics in both twins. However, if there is significant
epigenetic impact on viral evolution, then we would see
differences in the population dynamics and associated
population genetic parameters.
Results and Discussion
The phylogenetic analysis of env revealed clear evolu-
tionary differences between the viral populations present
in each twin (Figure 1), with twin A showing much
longer branch lengths compared to twin B. The viral
populations from each twin formed reciprocally mono-
phyletic groups with a shared most recent common
ancestor compared to HIV-1 control sequences (lab
reference sequences and the closest sequences identified
in BLAST analyses), as one would expect given the
same source population of HIV. Twin A also had much
high levels of genetic diversity compared to twin B
(Figure 1; Table 1). The phylogenetic network recon-
struction of rt (Figure 2) also indicates distinct viral
populations for each twin, with a relatively higher num-
ber of internal sampled genotypes in twin A in compari-
s o nw i t ht w i nB .T w i nBh a sah i g h e rn u m b e ro ft i p
haplotypes (although not statistically significant with a
P = 0.10; Fisher Exact Test), suggesting that selection is
acting with more force on twin B compared to twin A.
Both phylogenetic and network reconstruction analyses
showed similar results for all genes analyzed (env, pro
and rt) (data not shown). Growth rates were also differ-
ent between the HIV populations infecting the two
twins with twin A showing a rate, at least, two times
higher than twin B (Table 1). Interestingly, recombina-
tion rates were relatively similar except for rt where the
recombination rate (C) was three times higher in twin
A. In both twins the substitution rate was higher than
the recombination rate, as indicated by the low esti-
mates of r (c/μ). The ratio of the per-site rate of recom-
bination to the per-site rate of mutation (c/μ)i na l l
genes was less than one, indicating that mutation plays
a more significant role in producing novel genetic com-
binations than recombination and is, therefore, the
major force driving the evolution of these viral popula-
tions [see [18]]. Moreover, the BEAST analyses showed
that twin A had a higher relative genetic diversity than
twin B and showed different population dynamics
through time (Figure 3). In env, after a similar starting
point in both twins, the relative genetic diversity
remained constant until just recently when both twins
had a sudden decrease in diversity followed by an expo-
nential increase with twin A increasing to much higher
levels of diversity compared to twin B. In pro,b o t h
twins showed a gradual increase in the relative genetic
diversity until just after drug therapy intervention. Then
twin B starts to increase in diversity before twin A (per-
haps because twin B started drug therapy (AZT) two
years prior to twin A (ddI); see methods). Twin A then
has a steeper increase in diversity relative to twin B
before their levels come together at higher levels. In rt,
after a short initial starting point in both twins, twin A
rapidly develops higher diversity than twin B through
time with both patients showing increases in diversity
over the last two years, but twin A maintaining a rela-
tively higher level of diversity compared to twin B.
We also investigated the extent to which natural selec-
tion has impacted the viral populations for each twin.
Significant evidence of adaptive selection was detected
in rt from twin B (presumably associated with drug
resistance) and in env from twin A (presumably asso-
ciated with immune avoidance) using PAML (Table 2).
The Bayesian approach identified 11 positively selected
sites (pP > 0.95) under model M2 and 13 positively
selected sites under model M8 in env from twin A. All
of the 11 sites detected under model M2 were also
found by model M8. Models M2 and M8 also detected
one site under selection in rt from twin B (S162D). This
site is not documented as a drug resistance mutation
site in rt. Even though they are not detected as posi-
tively selected sites in rt,w ef o u n d ,i nb o t ht w i n s ,
M184V mutation that is associated with conferring
resistance to 3TC. Also we detected T215F and K219Q
mutations in rt in twin B, which are associated with
conferring resistance to AZT. There are 26 positions
known to be associated with protease inhibitors [19].
Some amino acid changes were seen in pro in both
twins, but none of these changes are known to confer
drug resistance. A recent study by Nozawa et al. [20]
pointed out the low sensitivity of PAML for detecting
positively selected sites, however this claim has been
rejected by Yang et al. [21] who provide strong support
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positive selection in DNA sequences and for compara-
tive analysis of genomic data [22]. Recombination can
confound the inference of selection. We, therefore,
tested for recombination using GARD (Genetic Algo-
rithm for Recombination Detection) that detected a sin-
gle recombination breakpoint in env for both twins and
in rt for twin B. The REL (Random Effect Likelihood)
selection analyses, that took into account the presence
of recombination inferred through GARD, clearly indi-
cated that in env, positive selection was stronger for
twin A, while no difference was detected in the other
genes (Table 3).
Our goal was to investigate HIV-1 evolution in identi-
cal twins infected synchronically at birth with the same
blood transfusion. We found compelling distinctions
between the viral populations from each twin with
respect to their population dynamics, phylogenetic
structure, growth rates, recombination rates, genetic
diversity, and selection pressures. These results were
unexpected due to a combination of having identical
starting points with respect to both the infecting viral
population and the host genetic background. That
coupled with the seemingly limited pathways of evolu-
tion for both immune evasion and evolution of drug
resistance [14,23] would lead one to predict similar
Figure 1 Midpoint-rooted phylogenetic tree of env sequences for the viral populations collected from both twins. Numbers above and
below branches indicate Maximum Likelihood (ML) bootstrap proportions and Bayesian posterior probabilities (as percentages), respectively.
Reference sequences (see main text for details) from the US are indicated by a star. Tree branch colors represent three sampled time points in
the env sequences for twin A and twin B (green: 09/15/1998, blue: 10/13/1998 and purple: 11/10/1998).
Table 1 Estimates of genetic diversity (θ), recombination (r and C), and growth (g) for pro, rt and env in each twin
Genes NS θ r (c/μ) Cg
Twin A pro 31 0.44 [0.23 - 0.92] 0.07 [0.02 - 0.17] 0.03 [0.005 - 0.16] 324 [222 - 426]
rt 28 0.26 [0.14 - 0.6] 0.23 [0.1 - 0.38] 0.06 [0.01 - 0.23] 177 [86 - 277]
env 33 0.2 [0.13 - 0.33] 0.03 [0.01 - 0.07] 0.01 [0.001 - 0.02] 42 [19 - 66]
Twin B pro 28 0.2 [0.09 - 0.71] 0.1 [0.003 - 0.47] 0.02 [0.0003 - 0.33] 175 [65 - 480]
rt 25 0.12 [0.07 - 0.24] 0.14 [0.04 - 0.25] 0.02 [0.003 - 0.06] 81 [27 - 165]
env 32 0.1 [0.06 - 0.16] 0.02 [0.01 - 0.07] 0.002 [0.001 - 0.01] 13 [(-18) - 41]
LAMARC’s confidence intervals (5% and 95%) around the estimates of each parameter are given between brackets. NS = Number of sequences.
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lations resulting in similar clinical outcomes. Instead, we
found higher growth rates, higher genetic diversity, and
higher recombination in rt in the healthier twin A com-
pared to twin B. We also found sites under diversifying
selection in env in twin A whereas twin B had only one
site under selection in rt (in PAML analysis). Thus, the
higher genetic diversity and higher number of selected
sites in env appear to be associated with slower disease
progression, results concordant with that found in a
broad study of disease progression in infants [24]. Simi-
larly, the twins differed in their population dynamics
and these differed by gene region. The rt and env
regions showed the viral population in the healthier
twin A with higher levels of genetic diversity throughout
the history of infection even when there were significant
shifts in overall levels of diversity. On the other hand,
pro showed the viral population in twin B with a gradual
increase in diversity post drug therapy with a more
rapid increase in twin A that was delayed by the same
time period as the delay in the RT inhibitor (2 years).
This result suggests that the shape of the response to
drug therapy in terms of the HIV population diversity
might be diagnostic of future disease progression, but
further study with larger sample sizes are needed to bet-
ter test this response as predictive of disease progres-
sion. Nevertheless, these twins clearly show very
different responses to infection.
This difference in viral population dynamics is concor-
dant with the differences observed in the clinical courses
in each twin. The immune system in twin A shows CD4 T
cells at an almost normal rate. The immune system in
twin B is depressed, hence no strong selective pressure is
acting upon its virus population to evolve fast [24]. All
these results combined provide strong evidence that, at
least in this case, the replicate evolutionary experiment did
Figure 2 Statistical parsimony network of rt in each twin. The network is constructed so that the colored squares and circles represent
actual cloned sequences. The size of the colored squares and circles is proportional to the number of sequences displaying the same genotype.
Each open circle represents putative sequences in the evolutionary pathway. The solid lines on a network represent mutational connections
among unique genotypes with at least a 95% degree of confidence, whereas the dashed lines represent a more tenuous connection. Different
colors in the network were used to represent three sampled time points in the rt sequences for twin A and twin B (green: 09/15/1998, blue: 10/
13/1998 and purple: 11/10/1998).
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importance of selective response to random epigenetic fac-
tors impacting disease progression [25].
Indeed, some studies in monozygotic twins revealed
increasing epigenetic differences with age [25,26]. Addi-
tionally, there is a clear potential for founding effects
upon infection [27], even in the context of a blood
transfusion as the viral population in a shared blood
donation is certainly reduced in genetic diversity and
number compared to infectious virus from an infected
individual. The combination of a reduced effective
population size coupled with strong selective pressure is
a key ingredient for founder effects [28,29], resulting in
populations with very different characteristics as evident
here in both the population dynamics and immunology.
Clearly, the early impact of founder effects and
epigenetic factors on viral population dynamics has
diversifying impact over time as the viral populations
undergo independent evolution - even in the face of
similar genetic selection pressures, identical genetic
starting points, and identical host genetic backgrounds
(Figure 1). This epigenetic drift during development can
be either stochastic (especially when impacted by
genetic drift) or determined by environmental factors
[30]. Host-virus interactions in early stages HIV infec-
tion are presumed to have a large impact on the disease
course and viral evolution [31-34], yet they are excep-
tionally difficult to study because researchers are typi-
cally not able to design experiments to investigate viral
dynamics at infection. Our study capitalizes on the
infection of monozygotic twins through a common con-
taminated blood transfusion to demonstrate that even
more complicated epigenetic factors need to be taken
into account in developing hypotheses associated with
genetic diversity, population dynamics, selection pres-
sure and their association with disease progression.
Conclusions
We used monozygotic twins infected at birth from the
same blood transfusion contaminated with HIV-1 to
study the association of population genetic and phyloge-
netic diversity with disease progression and clinical out-
comes. We documented that these twins had very
different clinical outcomes with twin A being relatively
healthy compared to twin B. Associated with this slower
disease progression in twin A, we found phylogenetic
differences, higher growth rates, and higher genetic
diversity in the HIV population and higher recombina-
tion rates in rt. We also found differences in population
dynamics across all three gene regions. These differ-
ences suggest that epigenetic factors are important in




Subjects A and B are monozygotic twins. Due to intra-
partum blood loss, they simultaneously received transfu-
sion shortly after birth from a common blood
transfusion source in 1983. The parents were notified
that the twins were infected with HIV when they were 2
years old and the twins were declared HIV positive in
the same year (1985). At that time, they were both
asymptomatic. No superinfection was reported during
the first five years of age of the twins. Also the twins
did not receive additional transfusions since their birth.
The twins came to NIH when they were 5 years old
(1988). Since then, they have been closely monitored at
NIH. The twins started receiving nucleoside analog
reverse transcriptase inhibitors at ages 5 (Twin B) and 7
Figure 3 Bayesian skyline plots of the past population
dynamics of HIV-1 in twins A (black lines) and B (red lines) for
env, pro and rt. Solid lines show the median estimate and dashed
lines the 95% highest posterior density limits.
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he was sicker than his brother. Twin A started ddI ther-
apy two years later (1990). Twin A is normal in terms
of immune system and growth. In contrast, twin B is 5
years delayed in terms of size and he presented a rare
neoplasm, more likely due to HIV infection. Blood sam-
ples and clinical information were obtained 15 years
after their birth at the NIH Clinical Center, Bethesda,
MD (1998). The twins subsequently showed extremely
different clinical courses. Samples were collected under
protocols approved by the institutional review boards at
the National Cancer Institute. Written informed consent
was obtained from participants. This research complied
with all relevant federal guidelines and institutional poli-
cies. Permission was obtained from the parents of the
patients for utilization of samples and data for research,
analysis and publication.
HIV-1 sequencing
Peripheral blood mononuclear cells (PBMCs) were isolated
from blood samples by Ficoll-Hypaque gradient density at
650 g for 30 min, and the cell pellets were stored in liquid
nitrogen until use. DNA was extracted from PBMCs using
the PureGene genomic DNA isolation kit (Gentra Systems,
Minneapolis, MN) and prepared at optimal concentration
for nested polymerase chain reaction (PCR) method.
Nested PCR amplification of the V1-V5 region of envelope
coding gene, the protease gene, and a part of reverse tran-
scriptase gene was performed with the Expand High Fide-
lity PCR System (Roche Applied Science, Indianapolis, IN)
in a 50 μ l reaction containing 1× Expand High Fidelity
buffer 3, 200 μ M dNTPs, 2 mM MgCl2, 400 nM primers,
and 1.75 U of Expand High Fidelity PCR System enzyme
mix. Primer sets used to amplify a 1.1-Kbp fragment,
encompassing the env V1-V5 region were: +6559 (sense)
5’-GGGATCAAAGCCTAAAGCCA-3’ and -7648 (anti-
sense) 5’- ACTTCTCCAATTGTCCCTCA-3’ in a first
round reaction; +6586 (sense) 5’- AATTA ACCCCA-
CTCTGTGTTA-3’ and -7627 (antisense) 5’-T A T C -
TCCTCCTCCAGGTCTGA-3’ in a second round reaction.
Amplification of the HIV-1 pro was done with the follow-
ing primer sets: +2165 (sense) 5’- CAGAAGAGAGCTT-
CAGGTTTGGG-3’ a n d- 2 5 8 8( a n t i s e n s e )5 ’- ACTTTT
GGGCCATCCATTCCTGGY-3’ in a first round reaction;
+2208 (sense) 5’-TCAGAAGCAGGAGCCGATAGAC-3’
and -2550 (antisense) 5’-TGGTACAGTCTCAATAGGAC-
TAATGGG-3’ in a second round reaction. The part of rt
was amplified with: +1882 (sense) 5’-GAAGCAAT
GAGCCAAGTAACAAAT-3’ and -3544 (antisense) 5’-
GATATGTCCATTGGCCTTGCCCCT-3’ in a first round
reaction; +1966 (sense) 5’-TTCAATTGTGGCAAAGA
AGGGCAC-3’ and -3501 (antisense) 5’-TAAGTCTTTT-
GATGGGTCATAATA-3’ in a second round reaction.
Each round of PCR consisted of 25 cycles, with the initial
denaturation at 94°C for 2 min, followed by 25 cycles of
denaturation at 94°C for 15 s, annealing at 50°C for 30 s,
and extension at 72°C for 1 min, with the final extension at
72°C for 7 min. The PCR products were purified with the
QIA quick PCR purification kit (QIAGEN, Valencia, CA),
and then cloned into pCR2.1-TOPO vector using the
TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA). The
clones for each gene were sequenced using the ABI BigDye
Terminator v3.1 Ready Reaction Cycle Sequencing Kit
(Applied Biosystems, Foster C i t y ,C A ) .S e q u e n c e sw e r e
then analyzed on an ABI PRISM 3130 × l Genetic Analyzer
(Applied Biosystems, Foster City, CA). GenBank accession
numbers for the sequences determined in this study are
GQ118464 to GQ118640.
Phylogenetic analysis and network reconstruction
Sequences from each twin were aligned using MAFFT
v5.3 [35] and manually edited using MacClade 4.05 [36].
Table 2 Log-likelihood values and parameter estimates (ω, p, and n) for pro, rt and env in each twin
Genes LnLM1 LnLM2 ωM2 pM2 PSSM2 LnLM7 LnLM8 ωM8 pM8 PSSM8
Twin A pro -634.3 -634.3 1 0 0 -634.3 -634.2 1 0 0
rt -1098 -1098 1 0 0 -1097.9 -1097.9 1 0 0
env -3552.5 -3526.5 3.6 0.19 11 -3553.4 -3526.6 3.3 0.25 13
Twin B pro -666.7 -666.7 1 0 0 -666.7 -666.7 1 0 0
rt -1444 -1441.8 5.8 0.02 1 -1444.1 -1441.7 5.4 0.02 1
env -3040.5 -3039.4 1 0 0 -3041 -3039.4 1 0 0
LnL = Likelihood values; ω = estimate of dN/dS (ωM2 and ωM8); p = proportion of sites under diversifying selection (pM2 and pM8); PSS = number of positively
selected sites with a posterior probability > 0.95 (PSSM2 and PSSM8). All comparisons between nested models (M1 vs M2, and M7 vs M8) were significant.
Table 3 Selection analyses for pro, rt and env in each
twin
Twin A Twin B
GARD ω* PSS* GARD ω* PSS*
env 237 1.19 20 650 0.54 0
pro – 0.31 0 – 0.30 0
rt – 0.24 0 317 0.36 0
The column GARD indicates the location of breakpoints, ω is the estimate of
dN/dS. PSS are positively selected sites for the REL analysis.
*If recombination was detected, the selection analyses were performed taking
into account the resulting partition.
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likelihood approach [37] with nodal support assessed via
bootstrapping (1,000 pseudoreplicates) [38], as imple-
mented in PHYML [39]. We also estimated phylogenies
using Bayesian methods [40] coupled with Markov
Chain Monte Carlo (BMCMC) inference as implemen-
ted in MrBayes v3.1.2 [41]. Model selection for these
analyses followed the procedure outlined by Posada and
Buckley [42] and implemented in ModelTest v3.6 (using
PAUP*) [43] under the Akaike Information Criterion
(AIC) [44]. Two independent BMCMC analyses were
run, each consisting of four MCMC chains (one cold
and three heated). Each Markov chain started from a
random tree and ran for 2.0 × 10
7 cycles, sampling
every 1000
th generation. In order to confirm that the
chains converged and mixed well, we monitored the
likelihood scores and compared means and variances of
all likelihood parameters from independent runs using
Tracer v1.4.1 [45]. The relatedness of the twins’ infec-
tions was assessed by adding 20 HIV-1 reference
sequences to the phylogenetic analysis: 11 lab reference
strains (HIVU455, HIVELI, HIVSC, HIVHXB2,
HIVJRFL, HIVJRCSF, HIVD31, HIVBRVA, HIVMN,
HIVNY5 and HIVSF2) and the nine closest sequence
matches (Sequence identity: 85%-95%) identified by
BLAST analyses (DQ410259, AF025761, AY247221,
DQ313246, AY247218, AY835759, EU184128,
HQ110637 and DQ410044). Evolutionary relationships
among the sequences in each twin were also assessed
using the method of statistical parsimony [46], as imple-
mented in the software package TCS v1.21 [47]. This
approach allows for the visualization of evolutionary
relationships as a network instead of a bifurcating tree
which is often more appropriate for viral populations
that recombine.
Population genetic parameters
Genetic diversity (θ =4 Neμ;w h e r eNe is the effective
population size and μ is the mutation rate per site),
recombination rates (r = c/μ;w h e r ec is the recombina-
tion chance per site), and growth rates (g)w e r ee s t i -
mated for each set of genes using the maximum
likelihood coalescent approach implemented in
LAMARC v2.0.2 [48]. Three independent runs were per-
formed for each gene in order to assess the reproduci-
bility of the different parameter estimates. Furthermore,
an estimate of the diversity generated per recombination
(C) was obtained by multiplying r and θ [18].
BEAST analyses
HIV-1 past population dynamics in each twin was
inferred using the Bayesian skyline plot [49] and relaxed
clock (lognormal) models [50] in BEAST v1.4.2 [51].
The rate of substitution was calibrated based on the age
of infection (15 years). The hyperparameter m (number
of grouped intervals) was set up to 1/4 of the sequences
in each dataset. All the Bayesian MCMC output gener-
ated by BEAST was then analyzed in Tracer v1.4.1 [45]
to test for convergence and mixing and plot population
demographics.
Selection analyses
The extent of natural selection was inferred by estimat-
ing the ratio of nonsynonymous to synonymous substi-
tutions (ω =d N/dS) per site and per gene using the
codon-based nested models M1 (neutral)/M2 (selection),
and M7 (beta)/M8 (beta and ω), as implemented in
PAML v4 [22]. Model likelihoods were compared using
a Likelihood Ratio Test (LRT) to determine the best-fit
model. The Bayes empirical Bayes approach was applied
to identify the potential sites under diversifying selection
as indicated by a posterior probability (pP >0 . 9 5 )[ 5 2 ] .
In order to confirm the PAML analysis, additional ω
estimates were also calculated in DataMonkey [53].
Positively and negatively selected sites were identified
using the REL approach [54]. Recombination was taken
into account by screening for recombination breakpoints
using GARD and allowing each recombinant fragment
to have its own phylogenetic tree [55].
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